Comparably to HER2, anti-EGFR antibodies and small molecule inhibitors are approved for clinical use for colorectal, head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.